首页 > 抗体蛋白 > 抗体
APC/Fire™ 750 anti-mouse CD8a Antibody
产品名称:
APC/Fire™ 750 anti-mouse CD8a Antibody
产品类别:
抗体
产品编号:
100765
产品应用:
100765
[价格]
规格 价格 库存
25µg ¥ 1176 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with APC/Fire? 750 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

* APC/Fire? 750 has a maximum excitation of 650 nm and a maximum emission of 787 nm.

Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  30. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Cibrián D, et al. 2020. J Allergy Clin Immunol. 145:199. PubMed
  2. Toomer G, et al. 2022. Viruses. 14:. PubMed
  3. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  4. Pan D, et al. 2022. Cancer Res. :. PubMed
  5. Liu X, et al. 2020. Nature. . PubMed
  6. Lee AK, et al. 2020. Radiat Res. 193:305. PubMed
  7. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  8. Marro BS, et al. 2019. Cell Rep. 29:3293. PubMed
  9. Ramos CV, et al. 2020. Cell Reports. 32(3):107910. PubMed
  10. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  11. Ficht X, et al. 2019. J Immunol. 203:2377. PubMed
  12. Yap JY, et al. 2018. Immunology. 154:522. PubMed
  13. Marinescu CI, et al. 2021. Stem Cell Res Ther. 12:319. PubMed
  14. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  15. Abbott RK, et al. 2018. Immunity. 48:133. PubMed
  16. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  17. Huang L, et al. 2018. Exp Neurol. 300:41. PubMed
  18. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
  19. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  20. Alter C et al. 2019. Am J Physiol Heart Circ Physiol. 317(1):H190-H200 . PubMed
  21. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  22. Knox T, et al. 2019. Sci Rep. 9:6136. PubMed
  23. Aryal B, et al. 2016. Nat Commun. 7:12313. PubMed
  24. Szeto C, et al. 2022. Nat Commun. 13:4951. PubMed
  25. Wirasinha RC, et al. 2021. J Exp Med. 218: . PubMed
RRID
AB_2572112 (BioLegend Cat. No. 100765) AB_2572113 (BioLegend Cat. No. 100766)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8a on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线